Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

In this page

Clinical Trial

NCT03507686 Completed
Gemini

An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral,Sequential Administration of Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1).

Phase 2
Interventional

Disease

Disease type

Choroideremia

Orphan drug recognition

Yes

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

29/11/2017

Closing date

29/06/2022

Inclusion criteria :

More

Exclusion criteria :

More

Funding

industry

Members involved

Main investigators

Others investigators

Dr Katarina Stingl

Representative

Germany

Low Vision Daily Life and Patients Groups (TWG5), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
See more

Prof. Dr. med. Karl Ulrich Bartz-Schmidt

Substitute

Germany

See more

Dr Susanne KOHL

Substitute

Germany

Genetic Diagnostics (TWG6), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
See more

ERN EYE member investigating site

HCP : Principal investigators

Centre for Ophthalmology, University Eye Hospital, Tübingen, Germany

Adress

Department für Augenheilkunde Tübingen Forschungsinstitut für Augenheilkunde Elfriede-Aulhorn-Str. 7

72076 Tübingen

Germany